AI Analysis | Feedback

• GW Pharmaceuticals for psychedelic medicines.
• An early-stage Moderna, but focused on psychedelic mental health drugs.

AI Analysis | Feedback

• SP-26 Program: Developing an intracerebral implant for controlled psilocybin delivery to treat Parkinson's Disease and other neurological disorders.
• SP-26/Ketamine Program: Investigating the combination of psilocybin and ketamine to address chemotherapy-induced peripheral neuropathy.
• SP-20 Program: Developing a proprietary psychedelic compound for the treatment of mood and anxiety disorders.
• SP-30 Program: Researching an LSD-derived compound for various neurological and psychiatric indications.

AI Analysis | Feedback

SILO Pharma (symbol: SILO) is a developmental stage biopharmaceutical company focused on the research and development of psychedelic-based therapeutics for neurological disorders and other indications.

As a pre-revenue company operating in the research and development phase, SILO Pharma does not currently have major customers or generate revenue from commercial product sales. Its primary activities involve preclinical studies and advancing drug candidates through early-stage clinical trials.

The company's business model is centered on developing promising intellectual property (drug candidates) with the long-term goal of licensing these assets to or partnering with larger pharmaceutical companies for further development, regulatory approval, and eventual commercialization. Therefore, while it does not currently have customers, its potential future collaborators or licensees would primarily be other companies within the pharmaceutical and biotechnology sectors.

AI Analysis | Feedback

null

AI Analysis | Feedback

Eric Weisblum, Chief Executive Officer and President

Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc.. Prior to Silo Pharma, Mr. Weisblum was a private investor and advisor to several of his portfolio companies. He has experience in both in-licensing therapeutic assets and assisting in their development, and possesses nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum also founded Whalehaven Capital LP in 2003 and is currently a Managing Member at Jaws Capital Partners LLC. He has served on the board of Aikido Pharma and was the president of Sableridge Capital.

Daniel Ryweck, Chief Financial Officer and Principal Accounting Officer

Daniel Ryweck is a Certified Public Accountant. He was formerly the chief compliance officer of Mill City Ventures III Ltd. from June 2014 to December 2019, and then served as Controller at the same company since January 2020. Mr. Ryweck also held the position of interim chief financial officer of Sun BioPharma, Inc., and served as a director of Dala Petroleum Corp. (later KonaTel Inc.) from July 2016 to September 2017.

Dr. James S. Kuo, M.B.A., M.D., Vice President of R&D

Dr. James Kuo currently serves as Managing Director of Athena Bioventures. He is an experienced biotech industry executive and investor who has held executive positions in both private and listed bioscience companies across the U.S., Canada, and Europe. Dr. Kuo has previously served as CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories. He currently serves as Chairman of the Board of ImmunoPrecise Antibodies and is a board director of Tryp Therapeutics.

AI Analysis | Feedback

The key risks to SILO Pharma's business are primarily associated with its status as a developmental-stage biopharmaceutical company and the inherent challenges in drug development and commercialization.

1. Clinical Development and Regulatory Approval Risk: As a developmental-stage biopharmaceutical company, SILO Pharma's success is highly dependent on the successful outcome of preclinical and clinical trials, as well as obtaining regulatory approvals from authorities like the FDA for its novel therapeutic candidates. The drug development process for its lead candidates, such as SPC-15 for PTSD and SP-26 for fibromyalgia, is lengthy, costly, and uncertain, with no guarantee of favorable results or eventual market approval.
2. Funding and Profitability Risk: SILO Pharma has a limited operating history and no history of profitable operations. Analysts do not anticipate the company will be profitable in the near future, indicating ongoing profitability challenges. The company will require significant additional funds to continue its research and development activities and commercialize any approved products, and there is a risk that it may not be able to obtain sufficient capital on favorable terms, or at all.
3. Market Challenges and Stock Performance: The company's stock has experienced significant volatility and has recently hit a 52-week low amid challenging market conditions. Furthermore, SILO Pharma has received notification from Nasdaq regarding non-compliance with the minimum bid price requirement, which, if not rectified, could impact its listing status and investor confidence.

AI Analysis | Feedback

The increasing establishment of state-regulated access models for natural psychedelic compounds for therapeutic use (e.g., psilocybin services in Oregon and Colorado). This trend creates an alternative pathway for patients to receive psychedelic-assisted therapy that bypasses the traditional pharmaceutical drug development and prescription model, potentially undermining the market for proprietary, FDA-approved psychedelic therapeutics that companies like SILO Pharma are developing.

AI Analysis | Feedback

SILO Pharma (symbol: SILO) is a developmental-stage biopharmaceutical company focused on novel therapeutics for neuropsychiatric and neurological disorders, including stress-induced psychiatric disorders, chronic pain conditions, Alzheimer's disease, and multiple sclerosis. The company is also involved in developing psychedelic-inspired therapies.

• Post-Traumatic Stress Disorder (PTSD) (SPC-15): The global market for PTSD treatments is a multi-billion dollar and underserved market. In 2021, the PTSD market was projected to reach $10.7 billion globally by 2026.
• Fibromyalgia and Chronic Pain (SP-26): The global market for fibromyalgia is currently valued at over $4 billion and is projected to reach $4.1 billion by 2032. Another estimate from 2021 projected this market to reach $3.6 billion by 2026 globally.
• Alzheimer's Disease (SPC-14): The global Alzheimer's disease treatment market is projected to grow to $30.8 billion by 2033.
• Multiple Sclerosis (SPU-16): The global multiple sclerosis market size was valued at USD 28.28 billion in 2024 and is projected to grow to USD 39.39 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 3.70% during the forecast period (2025-2033). Other estimates include a market size of USD 32.23 billion in 2025, expected to reach USD 38.97 billion by 2030 (CAGR of 3.87%), and reaching US$ 41 billion by 2033 from US$ 28.2 billion in 2022 (CAGR of 3.8%).
• Psychedelic Therapeutics Market (General): The global psychedelic therapeutics market size was valued at USD 2.2 billion in 2024 and is predicted to reach USD 9.6 billion by 2034, growing at a 15.6% CAGR. Other projections estimate the global market size at USD 3.07 billion in 2024, reaching USD 8.33 billion by 2032 with a CAGR of 13.30%, or USD 1,595.5 million in 2022, growing at a CAGR of 12.1% from 2023 to 2030.

AI Analysis | Feedback

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has several key drivers expected to contribute to its future revenue growth over the next 2-3 years. These drivers primarily revolve around the advancement of its drug pipeline and the strategic management of its digital assets.

1. Advancement and Commercialization of Lead Drug Candidates: The primary driver for Silo Pharma's future revenue growth is the progression and eventual commercialization of its lead therapeutic candidates, particularly SPC-15 for post-traumatic stress disorder (PTSD) and stress-induced anxiety, and SP-26 for fibromyalgia and chronic pain. The company has achieved positive bioanalytical and large-animal safety/toxicology results for SPC-15 and expects data from its IND-enabling GLP toxicology/toxicokinetic study in early 2026. Silo Pharma is finalizing a drug-device study for a microchip-based nasal spray for SPC-15 and plans for FDA follow-up in November 2025 and an Investigational New Drug (IND) submission in 2026, aiming for first-in-human Phase 1 trials. For SP-26, a time-release ketamine-loaded implant, positive neuropathic nerve pain reduction has been observed in small animal studies, and a safety evaluation study is underway to inform future trials. The company intends to utilize the FDA's streamlined 505(b)(2) regulatory pathway for both SPC-15 and SP-26 to expedite drug approval, targeting a large potential addressable market.
2. Expansion of the Drug Pipeline and New Product Launches: Beyond its lead candidates, Silo Pharma is expanding its pipeline, which presents additional future revenue opportunities. This includes preclinical programs such as SPC-14 for Alzheimer's disease and SPU-16, a CNS-targeting peptide for multiple sclerosis. Additionally, Silo Pharma has formed a 50/50 joint venture with Hoth Therapeutics to develop a first-in-class GDNF-based therapy targeting obesity and fatty liver disease, aiming at a significant global market. Successful development and launch of these additional therapies would introduce new revenue streams.
3. Strategic Management of the Digital Assets Treasury: Launched in August 2025, Silo Pharma's digital assets treasury program is designed to participate in the growth of cryptocurrency and to strengthen the company's capital resources. This strategy involves "staking for yield" and utilizing a hedged overlay to manage volatility while maintaining upside potential. Initial cryptocurrency purchases, including Bitcoin (BTC), Ethereum (ETH), Solana (SOL), and ResearchCoin (RSC), were made in September and October 2025. The income generated from staking and potential appreciation of these digital assets contribute to the company's financial strength and can be reinvested into its core biopharmaceutical research and development, thereby indirectly fueling future revenue growth from its drug pipeline.

AI Analysis | Feedback

• No significant share repurchases or authorized future repurchases have been publicly disclosed or appear to be a primary capital allocation strategy for SILO Pharma over the last 3-5 years, as indicated by a largely negative average buyback yield.

• In May 2025, Silo Pharma completed a public offering of 3,333,338 shares of common stock, or pre-funded warrants, generating approximately $2 million in gross proceeds.
• An S-1 registration was filed in October 2025 for the resale of up to 3,071,428 shares issuable upon warrant exercise from an October 1, 2025 financing, with a potential for approximately $2.38 million in gross proceeds to the company if fully cash exercised.
• Shareholders have experienced substantial dilution over the past year, with total shares outstanding increasing by 197%. The company also performed a 1:50 reverse stock split in September 2022.

• Silo Pharma received approximately $2 million in gross proceeds from a public offering of common stock and warrants completed in May 2025, intended for general working capital.
• The company has the potential to receive approximately $2.38 million in aggregate gross proceeds if warrants issued in an October 2025 financing are fully cash exercised.

• Silo Pharma launched a digital assets treasury strategy in August 2025 and made initial cryptocurrency purchases in Bitcoin, Ethereum, Solana, and ResearchCoin in September and October 2025, aiming to expand capital resources and participate in crypto growth.

• No significant capital expenditures have been explicitly reported or detailed in the available information over the last 3-5 years. The company's last 12-month Capex to Operating Cash Flow was reported as 0.0%, indicating minimal capital expenditure.